CLAIM #48256 · Pfizer Inc (PFE) · 2023Q2 earnings call · Aug 1, 2023 · due Dec 31, 2025
“Having said that, we will be informed in the back half of the year of our revenue performance, specifically as it relates to COVID. That will inform us the level of opportunity we have to expand our margins into ‘24 and ‘25 and beyond.”
David Denton · CFO
In context
“color on the cost adjustment program. Dave Denton: Yes. So, thank you for the question. Clearly, as we develop this program in the back half of ‘23, we look forward to sharing a lot more details as we cycle into ‘24 and give you a lot of, I’ll say, milestones as you think about both our cost and investment structure going forward. Importantly, as you know, we’re extremely excited about the Seagen acquisition that’s upcoming here. Upon approval, this will allow the Company to refocus its efforts and its investments to make sure that we’re squarely focused on battling cancer going forward. And we think there’s a big opportunity as we align our resources against that franchise in that battle to fight cancer and an opportunity for patients and importantly, an opportunity long term for Pfizer. Having said that, we will be informed in the back half of the year of our revenue performance, specifically as it relates to COVID. That will inform us the level of opportunity we have to expand our margins into ‘24 and ‘25 and beyond. That will allow us to step back and make sure that all of our costs, all our investments are aligned with those Seagen objectives as well as aligned to maximizing the performance of our in-line portfolio as well as the launches that are occurring as we speak in the back half of this year. So, again, we look forward to sharing a lot more to this from this. This will be balanced, as you well know between SI&A and R&D, and we’ll give you that specific breakdown and that specific information later this year and into next year. Operator: Next, we have Louise Chen with Cantor. Louise Chen: I wanted to ask you first on these COVID scenarios that you think could unfold in the second half ‘23. Any way you could share some of the big ones that you anticipate could potentially happen? And then, seco”
Verify independently
SEC filings for PFE ↗ · Claim quote is verbatim from the 2023Q2 earnings call.